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Short Report
Metabolic activation of 2-amino-1-methyl-6-phenylimidazo
[4,5-b]pyridine and DNA adduct formation depends on p53:
Studies in Trp53(1/1),Trp53(1/2) and Trp53(2/2) mice
Annette M. Krais1, Ewoud N. Speksnijder2,3, Joost P.M. Melis2,3, Rajinder Singh4, Anna Caldwell5,
Gonc¸alo Gamboa da Costa6, Mirjam Luijten2,3, David H. Phillips1 and Volker M. Arlt1
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3 Department of Human Genetics, Leiden University Medical Center, Leiden, 2300, The Netherlands, RC
4 Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester, LE2 7LX, United Kingdom
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The expression of the tumor suppressor p53 can influence the bioactivation of, and DNA damage induced by, the environmental
carcinogen benzo[a]pyrene, indicating a role for p53 in its cytochrome P450 (CYP)-mediated biotransformation. The carcinogen
2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), which is formed during the cooking of food, is also metabolically acti-
vated by CYP enzymes, particularly CYP1A2. We investigated the potential role of p53 in PhIP metabolism in vivo by treating
Trp53(1/1), Trp53(1/2) and Trp53(2/2) mice with a single oral dose of 50 mg/kg body weight PhIP. N-(Deoxyguanosin-8-yl)-
2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP-C8-dG) levels in DNA, measured by liquid chromatography-tandem mass
spectrometry, were significantly lower in liver, colon, forestomach and glandular stomach of Trp53(2/2) mice compared to
Trp53(1/1) mice. Lower PhIP-DNA adduct levels in the livers of Trp53(2/2) mice correlated with lower Cyp1a2 enzyme activity
(measured by methoxyresorufin-O-demethylase activity) in these animals. Interestingly, PhIP-DNA adduct levels were significantly
higher in kidney and bladder of Trp53(2/2) mice compared to Trp53(1/1) mice, which was accompanied by higher sulfotrans-
ferase (Sult) 1a1 protein levels and increased Sult1a1 enzyme activity (measured by 2-naphthylsulfate formation from 2-naph-
thol) in kidneys of these animals. Our study demonstrates a role for p53 in the metabolism of PhIP in vivo, extending previous
results on a novel role for p53 in xenobiotic metabolism. Our results also indicate that the impact of p53 on PhIP biotransforma-
tion is tissue-dependent and that in addition to Cyp1a enzymes, Sult1a1 can contribute to PhIP-DNA adduct formation.
The environment is becoming increasingly polluted with
chemicals that play an important role in many human cancers.
Genotoxic carcinogens from the environment can damage
DNA by binding covalently to it, which can lead to mutations.
The tumor suppressor TP53, which encodes p53, plays a cru-
cial role during cellular response to DNA damage by regulat-
ing various cellular processes such as cell cycle arrest,
apoptosis and DNA repair.1 Under genotoxic stress, cellular
levels of p53 protein increase via post-transcriptional mecha-
nisms and the ability of p53 to bind speciﬁc DNA sequences
is activated. p53 function disabled by mutations in the TP53
coding sequence might lead to the development of tumors.2
Many environmental carcinogens require metabolism (e.g.,
catalysed by cytochrome P450 [CYP] enzymes) to form reac-
tive electrophilic species capable of covalently binding to
DNA (i.e., DNA adduct formation). We found recently in
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human cells that p53 expression is linked to CYP1A1-
mediated metabolic activation of the environmental carcino-
gen benzo[a]pyrene (BaP).3 BaP-DNA adduct levels in
TP53(2/2) cells were signiﬁcantly lower than in TP53(1/1)
cells, which correlated with BaP-induced CYP1A1 expression
in these cells. Bypass of the need for metabolic activation by
treating cells with BaP-7,8-dihydrodiol-9,10-epoxide (BPDE),
the activated metabolite of BaP, resulted in similar adduct
levels in all cell lines, regardless of p53 status. In contrast, in
in-vitro experiments BaP-DNA adduct formation was higher
in livers and kidneys of Trp53(2/2) mice compared to
Trp53(1/1) mice, while treating with BPDE resulted in simi-
lar adduct levels in both mouse lines.4 The higher BaP-DNA
adduct levels in the livers of BaP-treated Trp53(2/2) mice
correlated with higher Cyp1a1 enzyme activity in these
animals.
Heterocyclic aromatic amines (HAAs) are carcinogenic
compounds formed during cooking of meat, ﬁsh and poul-
try.5 Among these HAAs is 2-amino-1-methyl-6-phenylimi-
dazo[4,5-b]pyridine (PhIP), which is mutagenic in several
screening assays6 and which induces colon, prostate and
mammary gland tumors in rats, which correspond to the
principal sites in humans associated with Western diet-
related cancer, implying that it could be a human carcino-
gen.5,7 The International Agency for Research on Cancer
(IARC) has classiﬁed PhIP as possibly carcinogenic to
humans (Group 2B).5 HAAs, including PhIP, form DNA
adducts after metabolic activation and CYPs (particularly
CYP1A2 but also CYP1A1) are the most important enzymes
in the initial oxidation of PhIP, leading to the formation of
N-hydroxy-PhIP (N-OH-PhIP) (see Supporting Information
Fig. 1).6 Further metabolism by N-acetyltransferases (NATs)
or sulfotransferases (SULTs) converts N-OH-PhIP into esters
capable of undergoing heterolytic cleavage to produce a nitre-
nium ion, which is the ultimate reactive species that reacts
with DNA.8 The major covalent DNA adduct detected
in vivo resulting from exposure of experimental animals
and humans to PhIP is N-(deoxyguanosin-8-yl)-2-amino-1-
methyl-6-phenylimidazo[4,5-b]pyridine (PhIP-C8-dG).9
In this study, we investigated the impact of Trp53 status on
the bioactivation of PhIP in Trp53(1/1), Trp53(1/2) and
Trp53(2/2) mice. These gene knock-out mouse models have
been shown to be particularly useful for studying Trp53 in car-
cinogenesis because p53 function is highly cell-type speciﬁc.2
PhIP-C8-dG was detected in DNA and quantiﬁed using liquid
chromatography-tandem mass spectrometry (LC-MS/MS)
selected reaction monitoring (SRM) mode. Tissue-speciﬁc
expression and activity of xenobiotic-metabolising enzymes
(XMEs) involved in PhIP metabolism were compared with
DNA adduct formation in the same tissue.
Material and Methods
Carcinogen and adduct standard
Synthesis of PhIP was performed at the Biochemical
Institute for Environmental Carcinogens, Prof. Dr. Gernot
Grimmer-Foundation (Grosshansdorf, Germany) according
to a method described previously.10 The synthesis of PhIP-
C8-dG and [13C10]PhIP-C8-dG was performed as reported.
11
Animal treatment
All animal experiments were conducted in accordance with
the law at the Leiden University Medical Center, Leiden, The
Netherlands, after approval by the institutional ethics com-
mittee. Trp53(1/1), Trp53(1/2) and Trp53(2/2) male
C57BL/6 mice were generated, housed, and genotyped as
reported.4,12 Groups of male Trp53(1/1), Trp53(1/2) and
Trp53(2/2) mice (3 months old; 25–30 g; n5 4/group) were
treated with a single oral dose of 50 mg/kg body weight (bw)
of PhIP dissolved in corn oil following a treatment protocol
used previously to study PhIP metabolism.10 Control mice
(n5 4) received solvent (corn oil) only. Animals were killed
24 hrs after treatment and their tissues (liver, lung, kidney,
colon, small intestine, bladder, forestomach and glandular
stomach) were collected, snap-frozen in liquid nitrogen, and
stored at 2808C until further analysis.
DNA adduct analysis by LC-ESI-MS/MS
DNA from whole tissue was isolated by a standard phenol-
chloroform extraction method. An LC-ESI-MS/MS method
to detect and quantify PhIP-C8-dG adducts in DNA was
adapted as described previously (see Supporting Information
File 1).11
Preparation of microsomal and cytosolic samples
Hepatic and renal microsomal and cytosolic fractions (n5 4)
were isolated as described4 in Supporting Information File 1.
What’s new?
Many environmental carcinogens must be metabolized to form reactive electrophilic species capable of damaging DNA. The
tumour suppressor p53 was shown to influence the cytochrome P450 (CYP)-mediated biotransformation of the environmental
carcinogen benzo[a]pyrene. The suspected carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), which is
formed during the cooking of food, is also metabolically activated by CYP enzymes. This study shows that expression of p53
influences the biotransformation of PhIP. Using a gene knockout mouse model, the authors show that the impact of p53 on
PhIP-DNA adduct formation is tissue-dependent and that, in addition to cytochrome P450 enzymes, sulfotransferases contrib-
ute to the bioactivation of PhIP.
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Figure 1. (a) Positive LC-ESI-MS/MS collision induced dissociation (CID) product ion spectrum of PhIP-C8-dG standard (1 ng/ml). The spectrum was
acquired after continuous infusion at a flow rate of 10 lL/min with a syringe pump. Typical LC-MS/MS SRM ion chromatograms for the determination
of PhIP-C8-dG in (b) a mixture of PhIP-C8-dG standard (1 ng/ml) and 0.49 ng (1000 fmol) of [13C10]PhIP-C8-dG internal standard on column and in (c)
50 lg liver DNA isolated from Trp53(1/1) mice treated with 50 mg/kg bw PhIP and 0.49 ng (1000 fmol) of [13C10]PhIP-C8-dG internal standard on
column. The SRM transitions monitored were m/z 490 to 374 for PhIP-C8-dG and m/z 500 to 379 for [13C10]PhIP-C8-dG. The analytical column was
eluted isocratically at a flow rate of 200 lL/min with water/acetonitrile (0.1% formic acid) (85:15, v/v). (d) Quantitative LC-ESI-MS/MS analysis of
PhIP-C8-dG in various tissues of Trp53(1/1), Trp53(1/2) and Trp53(2/2) mice after exposure to PhIP. Values are the mean6SD (n54). Statisti-
cal analysis was performed by one-way ANOVA followed by Tukey post-hoc test (*p<0.05, **p<0.01; different from Trp53(1/1) mice). [Color figure
can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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Measurement of Cyp1a enzyme activity
in hepatic and renal microsomes
Hepatic and renal microsomal samples were characterised for
Cyp1a1/2 activity by determining 7-ethoxyresoruﬁn O-dee-
thylation (EROD) activity and for Cyp1a2 by determining 7-
methoxyresoruﬁn O-demethylation (MROD) activity.13
Cyp1a enzyme activity was also measured with 3-cyano-7-
ethoxycoumarin (CEC) as substrate.14 Detailed descriptions
of methods are given in Supporting Information File 1.
Expression of Sult1a1 and Nat1/2 protein
by western blotting
Microsomal and cytosolic proteins were separated using
NuPage 4–12% Bis-Tris sodium-dodecyl sulfate (SDS)-poly-
acrylamide gels (Life Technologies), and Western blotting
was carried out as reported previously.4,15 Sult1a1 and Nat1/2
forms were detected with antisera raised in rabbit against
bacterial inclusion bodies of human SULT1A or NAT2 (Sup-
porting Information File 1).14
Measurement of Sult1a enzyme activity in renal cytosols
Renal cytosolic samples were characterised for Sult1a
activity by monitoring the formation of p-nitrophenol from a
50-phosphoadenosine 30-phosphosulfate (PAPS)-regenerating
system (Supporting Information File 1).16
Results
PhIP-induced DNA adduct formation in Trp53(1/1),
Trp53(1/2) and Trp53(2/2) mice
The formation of PhIP-C8-dG adducts was determined in
various organs by LC-MS/MS (Fig. 1). Figure 1a shows the
LC-ESI-MS/MS collision induced dissociation (CID) product
ion spectrum of PhIP-C8-dG standard whereas Figures 1b
and 1c show typical LC-MS/MS SRM ion chromatograms of
the internal [13C10]PhIP-C8-dG alone or after spiking liver
DNA isolated from Trp53(1/1) mice treated with 50 mg/kg
bw PhIP, respectively. No PhIP-C8-dG was detectable in con-
trol (untreated) mice (data not shown). PhIP-C8-dG adduct
levels were signiﬁcantly lower in liver, forestomach, glandular
stomach, and colon of Trp53(2/2) mice compared to
Trp53(1/1) mice while adduct levels in kidney and bladder
of Trp53(2/2) mice were signiﬁcantly higher than in
Trp53(1/1) mice (Fig. 1d). For liver adduct levels were
2.1-fold lower in Trp53(2/2) mice than in Trp53(1/1)
mice whereas for kidney they were 4.8-fold higher. Of note,
no inﬂuence of p53 on PhIP-DNA adduct formation was
observed in Trp53(1/2) mice, except for glandular stomach
in which similar adduct levels were found in Trp53(1/2)
and Trp53(2/2) mice (Fig. 1d).
Expression of PhIP metabolising enzymes
in Trp53(1/1), Trp53(1/2) and Trp53(2/2) mice
In rodents, CYP-mediated N-oxidation of PhIP occurs pri-
marily in the liver which leads via N-OH-PhIP to the forma-
tion of PhIP-C8-dG in DNA. Metabolic activation of PhIP is
catalysed mainly by CYP1A2, but also CYP1A1.6 Thus we
studied Cyp1a1 and Cyp1a2 enzyme activity in hepatic
microsomal fractions isolated from Trp53(1/1), Trp53(1/2)
and Trp53(2/2) mice. MROD activity, which is considered a
measure for Cyp1a2 enzyme activity, was signiﬁcantly lower
(2.7-fold) in the liver of PhIP-treated Trp53(2/2) mice rel-
ative to PhIP-treated Trp53(1/1) mice (Fig. 2a) which corre-
lates with the levels of PhIP-DNA adducts in the livers of
these animals. EROD and CEC activities are considered
measures of Cyp1a activity, measuring both Cyp1a1 and
Cyp1a2 enzyme activity. First, we found that PhIP treatment
led to a signiﬁcant induction of Cyp1a enzyme activity in liv-
ers of Trp53(1/1) and Trp53(1/2) mice, but not in
Trp53(2/2) mice (Fig. 2b). Second, we observed that Cyp1a
enzyme activity in PhIP-treated Trp53(2/2) mice was lower
than in Trp53(1/2) and Trp53(1/1) mice, although statisti-
cal signiﬁcance was observed only in the samples measured
with the CEC assay (Fig. 2c). Collectively these results show
that lower hepatic Cyp1a enzyme activity in Trp53(2/2)
mice correlates well with lower PhIP-DNA adduct formation
in the liver of these animals.
As Trp53 status also impacted on PhIP-DNA adduct for-
mation in the kidney (compare Fig. 1d) we next studied the
expression and activity of PhIP metabolising enzymes in
renal microsomal and cytosolic fractions. Due to the role of
Cyp1a2 as major phase I enzyme activating PhIP we meas-
ured MROD activity in renal microsomes. We found that
Cyp1a2 enzyme activity was strongly induced after PhIP
treatment in all mouse lines (Fig. 2d). Interestingly, MROD
activity was two-fold lower in Trp53(1/2) and Trp53(2/
2) mice relative to Trp53(1/1) mice (Fig. 2d) which did not
correlate with PhIP-DNA adduct formation in this organ
(compare Fig. 1d).
Previous studies have shown that the Cyp1a-mediated
metabolite N-OH-PhIP can be further activated by phase II
enzymes such as SULTs and NATs (see Supporting Informa-
tion Fig. 1).8 SULTs and NATs can convert N-OH-PhIP into
esters capable of undergoing heterolytic cleavage to produce
a PhIP-nitrenium ion which can bind covalently to DNA
forming PhIP-C8-dG. Using Western blotting we found
higher Sult1a1 protein levels in the kidney of Trp53(2/2)
mice compared to Trp53(1/1) mice (Fig. 3a). No such
changes in Sult1a1 protein levels were observed in hepatic
cytosolic samples, where there was no detectable expression.
This ﬁnding was unexpected as liver has been reported to be
a primary site of Sult1a1 expression.17 As the antibody was
raised against bacterial inclusion bodies of human SULT1A,
it is possible that the afﬁnity to detect mouse Sult1a1 protein
may be lower. However, differences in the organ-speciﬁc dis-
tribution of Sults in mice have been described.17
No change in Nat1/2 protein levels were observed between
mouse lines in hepatic and renal cytosolic samples (Fig. 3a).
This suggests that Trp53 status does not modulate the expres-
sion of Nats in either liver or kidney of these mice. As N-
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OH-PhIP is activated by SULT1A enzymes (i.e., SULT1A1
and SULT1A2 in humans)8 we determined Sult1a1 enzyme
activity in renal cytosols isolated from Trp53(1/1),
Trp53(1/2) and Trp53(2/2) mice. We found that Sult1a
enzyme activity was signiﬁcantly increased in PhIP-treated
Trp53(2/2) mice compared to Trp53(1/2) and Trp53(1/1)
mice exposed to PhIP (Fig. 3b). This increase in Sult1a
enzyme activity in Trp53(2/2) mice was in line with higher
Sult1a1 protein levels (compare Fig. 3a) and correlated with
enhanced PhIP-DNA adduct formation in the kidney of these
animals (see Fig. 1d).
Discussion
In this study, we have used Trp53(1/1), Trp53(1/2) and
Trp53(2/2) mice to investigate the effect of p53 on PhIP-
DNA adduct formation in vivo and to examine the expres-
sion and activity of key enzymes involved in PhIP metabo-
lism. We have conducted an in vivo study in order to take
into account the roles of route of administration, absorption,
renal clearance and tissue-speciﬁc expression and activity of
XMEs.18 PhIP-DNA adduct formation was observed in all tis-
sues investigated conﬁrming a previous study involving mul-
tiple PhIP doses.10 However, the degree of DNA binding in
various tissues of Trp53(1/1) mice was different between
the two studies which is likely to be attributed to the differ-
ent protocols (i.e., a single dose of 50 mg/kg bw PhIP versus
ﬁve daily doses). Interestingly, PhIP-induced DNA adduct
formation was altered differently in multiple organs of
Trp53(2/2) mice relative to Trp53(1/1) mice suggesting
that the inﬂuence of p53 is highly tissue-speciﬁc. Formation
of PhIP-C8-dG adducts were signiﬁcantly lower in liver, for-
estomach, glandular stomach and colon of Trp53(2/2) mice
compared to Trp53(1/1) mice while adduct levels in kidney
and bladder of Trp53(2/2) mice were signiﬁcantly higher
than in Trp53(1/1) mice. In lung and small intestine no
difference in PhIP-DNA adduct formation was observed
between mouse lines.
Mainly, Cyp1a2, but also Cyp1a1, are considered to be the
key enzymes responsible for N-oxidation of PhIP to N-OH-
PhIP,6 while N-OH-PhIP can be further activated by
Nats and Sults.8 Our data showed that lower PhIP-DNA
adduct levels in the livers of Trp53(2/2) mice relative to
Trp53(1/1) mice correlated with lower hepatic Cyp1a2
enzyme activity in the former animals. In contrast, higher
PhIP-C8-dG levels in the kidney of Trp53(2/2) mice relative
Figure 2. Measurement of microsomal enzymes metabolising PhIP
in the livers and kidneys isolated from Trp53(1/1), Trp53(1/2)
and Trp53(2/2) mice. Cyp1a enzyme activity was measured as (a)
MROD, (b) EROD as well as (c) CEC activity in hepatic microsomes
and (d) MROD activity in renal microsomes isolated from control
(untreated) mice (left panel) or mice treated with PhIP (right panel).
Values are the mean6SD of three independent determinations; 4
animals per genotype were analysed in three separate experi-
ments. RFU, relative fluorescence unit. Statistical analysis was per-
formed by one-way ANOVA followed by Tukey post-hoc test
(#p<0.05, versus control [untreated] mice; *p<0.05, **p<0.01,
different from PhIP-treated Trp53(1/1) mice).
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to Trp53(1/1) mice correlated with higher Sult1a1 protein
levels and higher Sult1a enzyme activity in the former ani-
mals. Thus, our results not only conﬁrm a previous study4
demonstrating an emerging role for p53 in Cyp-mediated
carcinogen metabolism in vivo but they also demonstrate the
potential impact of p53 function on other XMEs (i.e.,
Sult1a1) in carcinogen metabolism in vivo.
Studies investigating carcinogen-DNA adduct formation in
transgenic mice with altered Trp53 status are sparse.4,19 Car-
michael et al.19 observed a twofold increase in diethyl-
stilbestrol (DES)-induced DNA adduct formation in Trp53
(1/2) mice compared to Trp53(1/1), while Trp53(2/2)
mice were not examined. The authors concluded that small
differences in the protein expression of several Cyp enzymes
could have contributed to the alterations in DES-induced
adduct levels.19 We recently found that DNA adduct forma-
tion induced by BaP was signiﬁcantly higher in liver and kid-
ney of Trp53(2/2) mice than Trp53(1/1) mice while 3-
nitrobenzanthrone (3-NBA)-induced DNA adduct formation
was not altered in these mouse lines.4 These results could be
explained by different metabolic pathways leading to DNA
adduct formation. CYP1A1 is considered the key enzyme
responsible for the metabolic activation of BaP18 while the
most efﬁcient enzyme to activate 3-NBA is NAD(P)H:qui-
none oxidoreductase (NQO1).20 Higher BaP-DNA adduct
levels in the livers of Trp53(2/2) mice correlated with
increased Cyp1a enzyme activity in these animals.4 In addi-
tion, signiﬁcantly higher amounts of BaP metabolites were
formed ex vivo in hepatic microsomes from BaP-pretreated
Trp53(2/2) mice compared to wild-type animals.4 No differ-
ences were observed for 3-NBA-DNA adduct formation
between Trp53(1/1), Trp53(1/2) or Trp53(2/2) mice,
which was in line with unchanged Nqo1 enzyme activity.4
In human cells, p53 has been shown to impact on CYP1A1-
mediated bioactivation of BaP, but not on the metabolic activa-
tion of 3-NBA by NQO1.3,21 In human cells, in vitro loss of
p53 function (i.e., TP53(2/2) cells) resulted in considerably
lower BaP-DNA adduct levels compared to TP53(1/1) cells
after BaP exposure.3,21 We found that BaP-induced CYP1A1
expression in human cells was regulated through p53 binding
to a p53 response element (p53RE) in the regulatory region of
CYP1A1,3 thereby enhancing its transcription. Others have
found that in human cells p53 can induce the activity of
CYP3A4 or UGT2B7 via its binding to p53REs and subsequent
enhancement of gene transcription.22,23 However, the role of
p53 in CYP1A1-mediated metabolism of BaP is different
in vitro and in vivo.3,4 While the induction of Cyp1a1 via p53
binding to a p53RE in the regulatory region of Cyp1a1 fails to
explain the impact of p53 on BaP metabolism in the liver
in vivo,4 this mechanism could possibly be relevant for p53
function on Cyp1a2-mediated PhIP metabolism in the liver
(present study).
Our results indicate that Cyp1a2 does not have the same
role in DNA adduct formation by PhIP in the kidney. Here,
higher adduct levels in Trp53(2/2) mice than in Trp53(1/1)
can be explained by enhanced expression and activity of Sults
(e.g., Sult1a1). There is evidence of the expression of multiple
forms of Sult enzymes in mouse kidney, mainly Sult1d1, but
also Sult1a1, which have been linked to carcinogen-DNA
adduct formation in the kidney.8,24 To our knowledge this is
the ﬁrst study that suggests that Sult-mediated carcinogen acti-
vation can be linked to p53 function. The exact mechanism
remains to be determined, but these results conﬁrm an impact
of p53 on both Phase I and Phase II enzymes.
In summary, we found that p53 functions inﬂuence the bio-
activation of PhIP in vivo, indicating that gene-environmental
interactions need to be taken into account with regard to car-
cinogen metabolism. Results to date indicate that the cellular
impact of p53 on carcinogen metabolism depends on the agent
Figure 3. Measurement of cytosolic enzymes metabolising PhIP in
the livers and kidneys isolated from Trp53(1/1), Trp53(1/2) and
Trp53(2/2) mice. (a) Western blot analysis of Sult1a1 and Nat1/2
in hepatic and renal cytosols. Representative images of the West-
ern blotting are shown and at least duplicate analysis was per-
formed from independent experiments. Gapdh protein expression
was used as loading control for the cytosolic fractions and a repre-
sentative blot is shown. (b) Sult1a enzyme activity was measured
using a colorimetric assay with 2- naphthol. Values are the
mean6SD of three independent determinations; four animals per
genotype were analysed in three separate experiments. Statistical
analysis was performed by one-way ANOVA followed by Tukey
post-hoc test (*p<0.05, different from PhIP-treated Trp53(1/1)
mice).
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studied and the XMEs involved. Future investigations will need
to assess whether other environmental carcinogens activated
by Sults depend on p53 function and how p53 regulates the
expression of XMEs in vivo.
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